|
|
| | JNT-517 Basic information |
| Product Name: | JNT-517 | | Synonyms: | JNT-517;1-Piperidinecarboxamide, 3-[cyclopropyl[[[[2-fluoro-4-(trifluoromethoxy)phenyl]methyl]amino]carbonyl]amino]-, (3R)-;(3R)-3-[Cyclopropyl[[[[2-fluoro-4-(trifluoromethoxy)phenyl]methyl]amino]carbonyl]amino]-1-piperidinecarboxamide;(R)-3-(1-cyclopropyl-3-(2-fluoro-4-(trifluoromethoxy)benzyl)ureido)piperidine-1-carboxamide;Repinatrabit | | CAS: | 2837993-05-0 | | MF: | C18H22F4N4O3 | | MW: | 418.39 | | EINECS: | | | Product Categories: | | | Mol File: | 2837993-05-0.mol |  |
| | JNT-517 Chemical Properties |
| density | 1.424±0.10 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | pka | 13.022±0.46(predicted) | | form | Solid | | color | White to off-white | | InChIKey | FNRHWODWSBDOOY-CYBMUJFWSA-N | | SMILES | N(C1CC1)([C@@H]1CCCN(C1)C(=O)N)C(=O)NCC1C=CC(=CC=1F)OC(F)(F)F |
| | JNT-517 Usage And Synthesis |
| Uses | JNT-517 is an orally active, selective SLC6A19 allosteric inhibitor with an IC50 of 47 nM for human SLC6A19. JNT-517 can be used for the study of phenylketonuria (PKU)[1]. | | in vivo | JN-170 (precursor of JN-517) (50-250 mg/kg, po, single dose) increases the excretion of amino acids in urine in mouse models[2]. | Animal Model: | C57Bl/6J wild-type mouse[2] | | Dosage: | 50-200 mg/kg | | Administration: | po, single dose | | Result: | Increaesed the excretion of glutamine, histidine, and threonine i urine. |
| | References | [1] Dean G Brown, et al. Small molecule inhibitors of mammalian slc6a19 function. Patent WO2022192370A1.
[2] Wobst HJ, et al., SLC6A19 inhibition facilitates urinary neutral amino acid excretion and lowers plasma phenylalanine. JCI Insight. 2024 Nov 8;9(21):e182876. DOI:10.1172/jci.insight.182876 |
| | JNT-517 Preparation Products And Raw materials |
|